353 related articles for article (PubMed ID: 8637027)
21. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
22. Synergistic interactions of combinations of topotecan with standard drugs in primary cultures of human tumor cells from patients.
Jonsson E; Fridborg H; Nygren P; Larsson R
Eur J Clin Pharmacol; 1998 Sep; 54(7):509-14. PubMed ID: 9832291
[TBL] [Abstract][Full Text] [Related]
23. Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.
Scott J; Dorr RT; Samulitis B; Landowski TH
Cancer Chemother Pharmacol; 2007 May; 59(6):749-57. PubMed ID: 17333195
[TBL] [Abstract][Full Text] [Related]
24. Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Wildner O; Blaese RM; Morris JC
Hum Gene Ther; 1999 Nov; 10(16):2679-87. PubMed ID: 10566896
[TBL] [Abstract][Full Text] [Related]
25. Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.
van Waardenburg RC; de Jong LA; van Eijndhoven MA; Verseyden C; Pluim D; Jansen LE; Bjornsti MA; Schellens JH
J Biol Chem; 2004 Dec; 279(52):54502-9. PubMed ID: 15471886
[TBL] [Abstract][Full Text] [Related]
26. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Lamond JP; Wang M; Kinsella TJ; Boothman DA
Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):361-8. PubMed ID: 8892461
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
28. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
[TBL] [Abstract][Full Text] [Related]
29. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
30. Enhanced antitumor activity of irofulven in combination with 5-fluorouracil and cisplatin in human colon and ovarian carcinoma cells.
Poindessous V; Koeppel F; Raymond E; Cvitkovic E; Waters SJ; Larsen AK
Int J Oncol; 2003 Nov; 23(5):1347-55. PubMed ID: 14532976
[TBL] [Abstract][Full Text] [Related]
31. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
Kim MK; James J; Annunziata CM
BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
[TBL] [Abstract][Full Text] [Related]
32. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer.
Lidor YJ; Shpall EJ; Peters WP; Bast RC
Int J Cancer; 1991 Nov; 49(5):704-10. PubMed ID: 1937956
[TBL] [Abstract][Full Text] [Related]
33. Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
Smith KS; Folz BA; Adams EG; Bhuyan BK
Cancer Chemother Pharmacol; 1995; 35(6):471-82. PubMed ID: 7533669
[TBL] [Abstract][Full Text] [Related]
34. Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo.
Anzai H; Frost P; Abbruzzese JL
Cancer Res; 1992 Apr; 52(8):2180-5. PubMed ID: 1373105
[TBL] [Abstract][Full Text] [Related]
35. Topotecan-based combination chemotherapy for human malignant glioma.
Schmidt F; Schuster M; Streffer J; Schabet M; Weller M
Anticancer Res; 1999; 19(2A):1217-21. PubMed ID: 10368678
[TBL] [Abstract][Full Text] [Related]
36. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
37. Synergistic cytotoxicity of pyrazoloacridine with doxorubicin, etoposide, and topotecan in drug-resistant tumor cells.
Hu Y; Krishan A; Nie W; Sridhar KS; Mayer LD; Bally M
Clin Cancer Res; 2004 Feb; 10(3):1160-9. PubMed ID: 14871996
[TBL] [Abstract][Full Text] [Related]
38. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells.
Pei XH; Nakanishi Y; Takayama K; Bai F; Kawasaki M; Tsuruta N; Mizuno K; Hara N
Anticancer Drugs; 1997 Mar; 8(3):231-7. PubMed ID: 9095327
[TBL] [Abstract][Full Text] [Related]
39. Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells.
Liebmann JE; Fisher J; Teague D; Cook JA
Oncol Res; 1994; 6(1):25-31. PubMed ID: 7919549
[TBL] [Abstract][Full Text] [Related]
40. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials.
Tanizawa A; Fujimori A; Fujimori Y; Pommier Y
J Natl Cancer Inst; 1994 Jun; 86(11):836-42. PubMed ID: 8182764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
